AS1841674 | 836620-18-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: AS1841674
• 英文别名: 1-Cyclopentyl-6-fluoro-7-(oxan-3-ylamino)-4-oxoquinoline-3-carboxylic acid
• CAS: 836620-18-9
• 化学式: C₂₀H₂₃FN₂O₄
• 分子量: 374.412
• InChiKey: PDJIORUAUDKJDJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  78.9
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• Methods for inducing insulin production and uses thereof
  申请人：UNIVERSITE DE GENEVE

  公开号：EP2963108A1

  公开（公告）日：2016-01-06

  The invention relates to methods of inducing insulin production in delta-cells and/or converting delta-cells into insulin producing cells, as well as methods of preventing and/or treating diabetes and agents and compositions useful in said methods.

  本发明涉及在 delta 细胞中诱导胰岛素分泌和/或将 delta 细胞转化为胰岛素分泌细胞的方法，以及预防和/或治疗糖尿病的方法和在上述方法中有用的制剂和组合物。
• METHODS FOR INDUCING INSULIN PRODUCTION AND USES THEREOF
  申请人：Université de Genève

  公开号：EP3161126A1

  公开（公告）日：2017-05-03
• CO-ADMINISTRATION OF INHIBITORS TO PRODUCE INSULIN PRODUCING GUT CELLS
  申请人：The Trustees of Columbia University in the City of New York

  公开号：EP3906041A1

  公开（公告）日：2021-11-10
• [EN] METHODS FOR INDUCING INSULIN PRODUCTION AND USES THEREOF<br/>[FR] MÉTHODES POUR INDUIRE LA PRODUCTION D'INSULINE ET UTILISATIONS DE CEUX-CI
  申请人：UNIV GENEVE

  公开号：WO2016001822A1

  公开（公告）日：2016-01-07

  The invention relates to methods of inducing insulin production in delta-cells and/or converting delta-cells into insulin producing cells, as well as methods of preventing and/or treating diabetes and agents and compositions useful in said methods.
• [EN] CO-ADMINISTRATION OF INHIBITORS TO PRODUCE INSULIN PRODUCING GUT CELLS<br/>[FR] CO-ADMINISTRATION D'INHIBITEURS POUR PRODUIRE DES CELLULES INTESTINALES PRODUISANT DE L'INSULINE
  申请人：UNIV COLUMBIA

  公开号：WO2020142646A1

  公开（公告）日：2020-07-09

  Methods are described for producing enteroendocrine cells that make and secrete insulin in a subject by co-administering a Foxo1 inhibitor in combination with a Notch inhibitor or ROCK inhibitor, or both. Also described are pharmaceutical compositions comprising a combination of a Foxo1 inhibitor with a Notch inhibitor or ROCK inhibitor, or both. The described methods and compositions may be used to treat a disorder associated with impaired pancreatic function such as diabetes.